why choose us

First received: April 28, 2023

Clinical Trial: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)

Brief Summary: SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

Read more